Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Immunoglobulin kappa variable 1-33 is part of the variable region of the human immunoglobulin kappa light chain, which, combined with the variable heavy chain domain, forms the antigen-binding site of antibodies. These regions are assembled by V-(D)-J recombination and can undergo somatic hypermutation, enabling affinity maturation in response to antigen exposure. Their primary function is to contribute to antigen recognition and diversity in humoral immunity, but as isolated domains, they are not therapeutic targets on their own. The requested target "immunoglobulin kappa variable 1/OR-2" is not a standard or recognized entry, and appears to be incorrect or misnamed. The closest validated targets are members of the immunoglobulin kappa variable family, e.g., IGKV1-33.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Immunoglobulin kappa variable 1-33 (IGKV1-33).